

Name of the issue: Anupam Rasayan Limited

1	Type of issue (IPO/ FPO)	IPO
2	Issue size (Rs. in million)	7,600.00

3 **Grade of issue alongwith name of the rating agency**

Name	Not Applicable
Grade	

4	Subscription Level (Number of times) ⁽¹⁾	Overall 44.4332 <i>Source: Basis Minutes</i>
---	--	---

(1) Before technical rejections

5 **QIB holding (as a %age of total outstanding capital) as disclosed to stock exchanges**

Particulars	%
(i) On Allotment March 19, 2021	6.75%
(ii) at the end of the 1st Quarter immediately af of the issue (March 31, 2021)	7.49%
(iii) at the end of 1st FY (March 31, 2021)	8.96%
(iv) at the end of 2nd FY (March 31, 2022)	9.41%
(v) at the end of 3rd FY (March 31, 2023)	8.52%

(1) Will be updated in due course

6 **Financials of the issuer**

(Consolidated Rs. in Million)

Parameters	31-Mar-21	31-Mar-22	31-Mar-23
Net Sales/ Income from operations	8109	10660	16020
Net Profit after Minority Interest	699	1522	2168.5
Equity Capital	999	1002	1074.7
Reserves excluding revaluation reserves	14727	16266	22651.2

7 Trading status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE")

Particulars	Status
(i) at the end of 1st FY (March 31, 2021)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2022)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2023)	Frequently Traded

8 Change, if any, in directors of issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
During year ended March 31, 2021	-	
During year ended March 31, 2022	-	
During year ended March 31, 2023	-	

9 Status of implementation of project/ commencement of commercial production

Particulars	Remarks
(i) as disclosed in the offer document	
(ii) Actual implementation	Not Applicable
(iii) Reasons for delay in implementation, if any	

10 Status of utilization of issue proceeds

Particulars	Total estimated amount / expenditure	Amount to be deployed from the Net Proceeds in Fiscal 2022
Repayment/prepayment of certain indebtedness availed by our Company (including accrued interest)	5,636.98	5,636.98
General corporate purposes	1,963.02	1,963.02
Total Net Proceeds	7,600.00	7,600.00

(ii) Actual utilization ⁽¹⁾	7,600.00
(iii) Reasons for deviation, if any	NA

(1) Information shall be updated in due course

11 Comments of monitoring agency, if applicable ⁽¹⁾

(1) Information shall be updated in due course

12 Price-related data

Designated SE	BSE
Issue Price (Rs.)	555
Listing Date	March 24, 2021

Price parameters	At close of listing day March 24, 2021	At close of 30th calendar day from listing day April 18, 2021	At close of 90th calendar day from listing day Jun 17, 2021 ⁽¹⁾	As at the end of March 31, 2021		
				Closing price during FY	High during FY	Low during FY
Market Price	525.90	552.15	741.15	490.45	548.95	472.25
Sensex	49,180.31	47,949.42	52,323.00	49,509.15	52,516.76	29,505.33
Sectoral Index	Not comparable to any of the available sectoral indices					
Price parameters	As at the end of March 31, 2022			As at the end of March 31, 2023		
	Closing price during FY	High during FY	Low during FY	Closing price during FY	High during FY	Low during FY
Market Price	822.45	1,106.00	493.00	864.3	928.0	547.1
Sensex	58,568.51	62,245.43	47,204.50	58,991.5	63583	50,921.0
Sectoral Index	Not comparable to any of the available sectoral indices					

Source: Stock Exchange data. Where the 30th day / 90th day / March 31 of a particular year falls on a holiday, the immediately following trading day has been considered

13 Basis for Issue Price and Comparison with Peer Group & Industry Average

Accounting ratio	Name of company	Face Value (Rs.)	As disclosed in the offer document	At the end of 1st FY March 31, 2021	At the end of 2nd FY March 31, 2022	At the end of 3rd FY March 31, 2023
Basic and Diluted EPS	Issuer: Consolidated	10	6.94	8.51	15	21
	Peer Group:					
	PI Industries Limited	1	33.08	49.92	56	81
	Navin Fluorine International Limite	2	82.6	52.03	53	75
	Astec Lifesciences Limited	10	24.29	33.23	46	13
	SRF	10	177.29	205.54	64	72
	Industry Avg			79.32	85.18	54.60
P/E	Issuer: Consolidated	10	79.97	57.3	54.8	41
	Peer Group:					
	PI Industries Limited	1	65.72	45.16	50.69	41
	Navin Fluorine International Limite	2	32.2	52.86	77.02	37
	Astec Lifesciences Limited	10	42.73	30.1	38.09	56
	SRF	10	30.58	26.3	42.01	106
	Industry Avg			42.81	42.81	51.95
RoNW%	Issuer:Consolidated	10	9.62	4.47	8.81	9.14
	Peer Group:					
	PI Industries Limited	1	17.43	13.82	13.79	17.08
	Navin Fluorine International Limite	2	28.93	15.76	14.26	17.17
	Astec Lifesciences Limited	10	19.25	21.04	22.67	6.1
	SRF	10	20.66	17.47	22.05	20.94
	Industry Avg:			21.57	17.02	18.19
NAV per share based on balance sheet	Issuer:Consolidated	10	76	157.5	172.34	220
	Peer Group:					
	PI Industries Limited	1	189.64	352.13	402.66	473
	Navin Fluorine International Limite	2	285.38	330.06	372.13	440
	Astec Lifesciences Limited	10	126.17	157.99	202.33	214
	SRF	10	858.26	1157.3	288.00	348
	Industry Avg:			364.86	499.37	316.28

Source Prosepctus

14 Any other material information

Particulars	Date
Anupam Rasayan to acquire stake in Tanfac Industries from Birla Group Holdings Private Limited and Others <i>Source- Stock Exchange filings</i>	01-02-2022

For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com